Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.84% | 58.96% | 59.04% | 69.14% | 62.64% |
| Total Depreciation and Amortization | 0.45% | -6.09% | -1.08% | 5.65% | 5.46% |
| Total Amortization of Deferred Charges | 677.63% | 682.67% | 777.33% | 221.62% | 4.11% |
| Total Other Non-Cash Items | -24.83% | -19.51% | -2.47% | -2.56% | 2.65% |
| Change in Net Operating Assets | 110.05% | 166.68% | 209.37% | 90.40% | -189.00% |
| Cash from Operations | 59.84% | 119.78% | 120.17% | 94.45% | 25.13% |
| Capital Expenditure | 97.27% | 78.95% | 100.00% | 75.81% | -13.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 97.27% | -600.00% | 100.00% | 75.81% | -13.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.03% | -93.95% | -55.60% | -80.24% | -97.64% |
| Repurchase of Common Stock | 75.00% | -650.00% | -27.27% | 100.00% | 99.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 81.85% | -- | -1,232.79% | -- |
| Cash from Financing | -99.75% | -2.22% | -55.76% | 2,623.53% | -72.33% |
| Foreign Exchange rate Adjustments | 271.77% | -265.24% | 137.77% | 827.66% | -473.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.86% | 114.20% | 122.47% | 123.09% | -111.85% |